The Pharma Data

AUGUST 30, 2021

Results were presented at the ESC Congress 2021, organized by the European Society of Cardiology (ESC). This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. reduction in LDL-C from baseline to Day 510 compared with placebo ( P < 0001) 1.

RNA 52

RNA Trials Production Containment 52

The Pharma Data

DECEMBER 12, 2020

More recently, AstraZeneca has increased its efforts in immunology research and the development of medicines for immune-mediated diseases. AstraZeneca has developed a broad range of technologies, initially focused on small molecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics.

Development 75

Development Regulation Medicine Containment 75

The Pharma Data

AUGUST 29, 2020

Presented at the ESC Congress 2020, the annual meeting of the European Society of Cardiology, the analysis evaluated the efficacy and tolerability of inclisiran on top of a maximally tolerated dose of statins, in two studies of more than 2,300 patients (of which 1,164 were on inclisiran) from the Phase III trials.

Medicine 52

Medicine Containment Trials Production 52

The Pharma Data

JANUARY 12, 2021

Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Securities Act of 1933, as amended. Forward Looking Statements.

Containment 52

Containment Development Sales Production 52

The Pharma Data

OCTOBER 25, 2020

Furthermore, we will advance the field of native lung recovery and improve patient outcomes by collecting critical research data and developing and teaching best practices.”. This press release contains forward-looking statements. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. FORWARD-LOOKING STATEMENTS.

Cardiology 52

Cardiology FDA Approval Production Engineer 52

pharmaphorum

FEBRUARY 26, 2021

Its founder, Dr Paul Janssen, is recognised as one of the most innovative and prolific pharmaceutical researchers of the 20th century. Dr Paul Janssen is recognised as one of the most innovative and prolific pharmaceutical researchers of the 20th century”. It was in 1961 that Belgium’s Janssen Pharmaceutica N.V.

Sales 126

Sales Production Pharma Companies Marketing 126

The Pharma Data

NOVEMBER 4, 2020

Expanded m edical society recommendations in support of the efficacy and safety of VASCEPA : The European Society of Cardiology expanded their guidelines to recommend use of VASCEPA in treating acute coronary syndrome patients. Research and development (R&D) expense for the three and nine months ended September 30, 2020 were $10.2

Sales 40

Sales Production Cardiology Marketing 40

The Pharma Data

OCTOBER 14, 2020

Michael Felker, MD, MHS, FACC, FAHA, FHFSA is Professor of Medicine with tenure in the Division of Cardiology at Duke University School of Medicine. He is Director of Cardiovascular Research at the Duke Clinical Research Institute and Vice-Chief for Clinical Research in the Division of Cardiology.

Cardiology 40

Cardiology Clinical Trials Clinical Trials Medicine 40

The Pharma Data

NOVEMBER 16, 2020

The “polypill” containing three generic blood pressure medications and a statin dramatically reduced the risk of heart-related illness in people with no prior history of heart problems, according to clinical trial results. The polypill/aspirin combination reduced heart problems and deaths by 31%, the researchers discovered.

Doctors 52

Doctors Doctor Cardiology Pharma Companies 52

XTalks

JANUARY 19, 2024

Radiobiological and Clinical Considerations from CRO and Emerging Biotech Radiopharmaceuticals are medicinal formulations containing radioisotopes that are used in the field of nuclear medicine primarily for the diagnosis and treatment of various diseases, particularly cancer. In addition, the cascades can also contain beta emissions.

DNA 66

DNA Radiology FDA Approval Development 66

XTalks

AUGUST 2, 2023

We delve into the driving forces behind their successes and shed light on the groundbreaking research that has earned them a place among the elite in the pharmaceutical arena. It contains the antiviral medications nirmatrelvir and ritonavir. Pfizer’s total global revenue from Paxlovid was $18.93 billion in 2022. and $16,382.51

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

APRIL 15, 2021

Dr. Benoit Tyl, MD, FESC, medical and scientific director, cardiology at Servier, says that the disconnect between correlation and causality in cardiovascular disease trials is partially responsible for the lack of approved HFpEF therapies. However, these drugs have shown limited effectiveness in treating HFpEF.

Development 98

Development Drugs Genome Genomics 98

The Pharma Data

SEPTEMBER 15, 2020

I am proud of the truly transformational science that our research and clinical teams are bringing to the fight against disease, as well as the unprecedented speed with which we are advancing our clinical programs in the battle against COVID-19. Disclosure Notice: The information contained in this release is as of September 15, 2020.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

The Pharma Data

OCTOBER 29, 2020

Research and Development. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Forward-Looking Statement.

Sales 40

Sales Clinical Trials Clinical Trials Production 40

The Pharma Data

APRIL 26, 2021

Topline results will be presented at the American College of Cardiology 70th Annual Scientific Session. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. The safety profile of Entresto was confirmed. Novartis will continue to evaluate the data.

Sales 40

Sales Medicine Production Manufacturing 40

The Pharma Data

MAY 13, 2021

Fructose Containing Sugars at Normal Levels of Consumption Do Not Effect Adversely Components of the Metabolic Syndrome and Risk Factors for Cardiovascular Disease. Experimental Diabetes Research. Effects of almond consumption on the reduction of LDL-cholesterol: a discussion of potential mechanisms and future research directions.

Insulin 52

Insulin Production Hormones Medicine 52